Daniel O'Connell
2023
In 2023, Daniel O'Connell earned a total compensation of $3.9M as Chief Executive Officer at Acumen Pharmaceuticals, a 48% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $427,277 |
|---|---|
| Option Awards | $2,190,177 |
| Salary | $597,590 |
| Stock Awards | $696,540 |
| Other | $18,427 |
| Total | $3,930,011 |
O'Connell received $2.2M in option awards, accounting for 56% of the total pay in 2023.
O'Connell also received $427.3K in non-equity incentive plan, $597.6K in salary, $696.5K in stock awards and $18.4K in other compensation.
Rankings
In 2023, Daniel O'Connell's compensation ranked 194th out of 3,006 executives tracked by ExecPay. In other words, O'Connell earned more than 93.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 194 out of 3,006 | 94th |
Division Manufacturing | 103 out of 1,650 | 94th |
Major group Chemicals And Allied Products | 67 out of 918 | 93rd |
Industry group Drugs | 66 out of 881 | 93rd |
Industry Biological Products, Except Diagnostic Substances | 23 out of 213 | 89th |
Source: SEC filing on April 22, 2024.
O'Connell's colleagues
We found two more compensation records of executives who worked with Daniel O'Connell at Acumen Pharmaceuticals in 2023.